The neuroblastoma associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK translocated cancers

The ALK kinase inhibitor crizotinib (PF-02341066) is clinically effective in patients with ALK-translocated cancers, but its efficacy will ultimately be limited by acquired drug resistance. Here we report the identification of a secondary mutation in ALK, F1174L, as one cause of crizotinib resistanc...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Sasaki, Takaaki, Okuda, Katsuhiro, Zheng, Wei, Butrynski, James, Capelletti, Marzia, Wang, Liping, Gray, Nathanael S., Wilner, Keith, Christensen, James G., Demetri, George, Shapiro, Geoffrey I., Rodig, Scott J., Eck, Michael J., Jänne, Pasi A.
Format: Artigo
Jezik:Inglês
Izdano: 2010
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC3045808/
https://ncbi.nlm.nih.gov/pubmed/21030459
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-10-2956
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki